No Data
No Data
Hualan Biological Engineering's Blood Centers Get License to Operate
Two of Hualan Biological Engineering's (SHE:002007) blood collecting centers are now allowed to operate after receiving licenses from the health commission of China's Henan Province, the company said
A subsidiary of Hualan Biology (002007.SZ) obtained a single plasma collection license
Zhitong Finance App News, Hualan Biology (002007.SZ) announced that on May 15, 2024, Hualan Biotech Qixian Single Plasma Collection Station and Hualan Biotech Xiangcheng Single Plasma Collection Station, which are affiliated with the company, obtained the “Single Plasma Collection License” issued by the Henan Provincial Health Commission.
Hualan Biological Engineering Inc.'s (SZSE:002007) Top Owners Are Retail Investors With 38% Stake, While 29% Is Held by Private Companies
Key Insights Significant control over Hualan Biological Engineering by retail investors implies that the general public has more power to influence management and governance-related decisions The to
Hualan Biology (002007.SZ): Intravenous human immunoglobulin (IVIG) (10%) is in phase III clinical trials
Gelonghui, April 15 | Hualan Biology (002007.SZ) said on the investor interactive platform that intravenous human immunoglobulin (IVIG) (10%) developed by the company is in phase III clinical trials.
Is Hualan Biological Engineering (SZSE:002007) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart m
Hualan Biological Engineering's Profit Rises 38%; Tops EPS, Revenue Estimates
Hualan Biological Engineering's (SHE:002007) attributable profit rose 37.66% to 1.48 billion yuan in 2023 from 1.08 billion yuan in 2022, according to a Tuesday filing with the Shenzhen bourse. Earnin
No Data